Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 2, 2026
- Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, versus $22.5 million a year earlier. Cash, cash equivalents and investments totaled $403.8 million at September 30, 2026, expected to fund operations into 2029.
- 10-Q report · filed Nov 2, 2026
- Seaport Therapeutics reported a $114.4 million nine-month net loss and $403.8 million in cash, cash equivalents and investments, which management believes will fund operations into 2029 after its IPO.
The audio replay and transcript follow the call.